Trial Profile
Osimertinib in pre-treated poor PS patients with T790M-positive advanced NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Mar 2022 Status changed from active, no longer recruiting to completed.
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 28 Sep 2019 Status changed from recruiting to active, no longer recruiting.